This work provides a rationale for combining BRCA2 ASO and olaparib treatment and extends the applicability of olaparib clinically, which up until now has been used primarily in the context of BRCA1 or 2 mutated ovarian cancers. This evidence concerns the gene BRCA2 and ovarian cancer.